bone metastases - malecare.org

On The Horizon- Coming Soon – Radium-223 (Alpharadin) A Bone Targeted Treatment for Advanced Prostate Cancer that Extends Life

At the recent European Multidisciplinary Cancer Congress in Stockholm, Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-related event (SRE) AND an overall survival (OS) benefit for those men with advanced prostate cancer taking radium-223 (Alpharadin). The real significance of [...]

By Malecare|2011-10-04T15:33:19-04:00October 4th, 2011|abiraterone acetate, Advanced Prostate Cancer, Alpharadin (radium-223), bisphosphonates, Cabazitaxel, Chemo Therapy Failure, Clinical Trials, Clinical Trials, denosumab - Xgeva, Drugs & Treatments, On The Horizon, Uncategorized, Zometa|1 Comment

On the Horizon – Denosumab (Xgeva) to Slow the Development of Bone Mets

Amgen has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the indication for denosumab (XGEVA) its RANK ligand inhibitor to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, denosumab would be the first therapy licensed to prevent or delay the spread of cancer [...]

By Malecare|2011-07-13T12:16:49-04:00July 13th, 2011|Advanced Prostate Cancer, denosumab - Xgeva, Drugs & Treatments, FDA, On The Horizon, Uncategorized, Understanding APC|0 Comments

On The Horizon – Xgeva (denosumab) To Prevent or Slow Down Bone Mets

Yesterday, Amgen announced that it had submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand its license for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or [...]

By Malecare|2011-06-27T23:08:22-04:00June 27th, 2011|Advanced Prostate Cancer, bisphosphonates, Clinical Trials, Clinical Trials, denosumab - Prolia, denosumab - Xgeva, Drugs & Treatments, FDA, Metastases, On The Horizon, Uncategorized, Understanding APC|0 Comments

Zoledronic Acid Therapy Impacts Risk and Frequency of Skeletal Complications In Men with Prostate Cancer – Start Early Therapy

To evaluate the effects of timing and length of zoledronic acid (ZA) treatment on outcomes for men with prostate cancer, researchers from the University of Illinois at Chicago and the Hind T. Hatoum & Company, Chicago, IL. evaluated a large contingent of men who had been diagnosed with prostate cancer from January 2003 to October [...]

By Malecare|2010-12-28T11:32:31-05:00December 28th, 2010|Advanced Prostate Cancer, bisphosphonates, Drugs & Treatments, General Information, Metastases, Research, Uncategorized, Understanding APC, Zometa|1 Comment

Zoledronic Acid Shows Improved Clinical Outcomes When Administered Prior to Bone Pain in Men with Advanced Prostate Cancer

According to the FDA approval label, zoledronic acid (Zometa) should be administered to men with advanced prostate cancer once they have failed one hormone therapy type, in other words, once the cancer has become castrate resistant. Researchers at the Centre Hospitalier de i’Université de Montréal, Hôpital Notre-Dame, Montréal, Quebec, Canada evaluated the effect of zoledronic [...]

By Malecare|2017-10-19T10:53:24-04:00December 15th, 2010|Advanced Prostate Cancer, bisphosphonates, Drugs & Treatments, General Information, Metastases, Uncategorized, Understanding APC, Zometa|2 Comments